Excessive circulating FAs have been proposed to promote
insulin resistance (IR) of
glucose metabolism by increasing the oxidation of FAs over
glucose. Therefore, inhibition of FA oxidation (FAOX) has been suggested to ameliorate IR. However, prolonged inhibition of FAOX would presumably cause
lipid accumulation and thereby promote lipotoxicity. To understand the glycemic consequences of acute and prolonged FAOX inhibition, we treated mice with the
carnitine palmitoyltransferase 1 (CPT-1) inhibitor,
etomoxir (eto), in combination with short-term 45% high fat diet feeding to increase FA availability. Eto acutely increased
glucose oxidation and peripheral
glucose disposal, and lowered circulating
glucose, but this was associated with increased circulating FAs and
triacylglycerol accumulation in the liver and heart within hours. Several days of FAOX inhibition by daily eto administration induced hepatic steatosis and
glucose intolerance, specific to CPT-1 inhibition by eto. Lower whole-body
insulin sensitivity was accompanied by reduction in brown adipose tissue (
BAT) uncoupling protein 1 (
UCP1) protein content, diminished BAT
glucose clearance, and increased hepatic
glucose production. Collectively, these data suggest that pharmacological inhibition of FAOX is not a viable strategy to treat IR, and that sufficient rates of FAOX are required for maintaining liver and BAT metabolic function.